Arndt Vogel, Head of the Center for Personalized Medicine, MHH at Medical University of Hanover, shared a post on X:
“Zolbetuximab plus gemcitabine and nab-paclitaxel in CLDN18.2+ metastatic PDAC – phase II GLEAM study:
- Primary endpoint not met, no OS and PFS benefit
- Toxicity manageable
- Not the right drug, but maybe the right target.”
Jose Tapia, Medical Oncologist at Velindre University NHS Trust, shared Arndt Vogel’s post, adding:
“Ph2 Zolbetuximab + GN in PDAC increased nausea, vomiting and hypoAlb (>10%).
These AEs appear early. In an already nutritionally depleted population, they may worsen nutrition, impacting OS or Tx duration despite early responses. Proactive AE management is key.”
You can also read:
